VCNX · Vaccinex, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“We will require additional capital to finance our operations to continue as a going concern, which may not be available to us on acceptable terms, if at all. As a result, we may not complete the development and commercialization of our product candidates or develop new product candidates and have substantial doubt about our ability to continue as a going concern.”View the 10-K filed Apr 15, 2025
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Feb 20, 2024; bars on opposite sides are not compared.
The closing range begins at the captured split on Feb 20, 2024.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VCNX
this stock
Vaccinex, Inc.
|
$2.94M | — | +5.4% | — | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +19.5% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +2.9% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$63.63B | +21.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.23B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.0%
- Net QoQ
- -335.5K sh
- Top holder
- BARCLAYS PLC
Performance
Raw-price comparisons begin at the captured split on Feb 20, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VCNX | -73.8% | -67.5% | -83.7% | -72.0% | — |
| SPY | -3.5% | -0.7% | +7.7% | -2.7% | +23.4% |
| vs SPY | -70.3% | -66.8% | -91.4% | -69.3% | — |